Tags

Type your tag names separated by a space and hit enter

Early monitoring of fatty acid profile in children with attention deficit and/or hyperactivity disorder under treatment with omega-3 polyunsaturated fatty acids.
Minerva Pediatr. 2019 Aug; 71(4):313-325.MP

Abstract

BACKGROUND

Cognitive effects of omega-3 polyunsaturated fatty acids (ω-3 PUFAs) might make them helpful in attention deficit/hyperactivity disorder (ADHD). However, the results derived from supplementation studies in children depend on the respective combinations and the study period. We aimed to investigate the serum fatty acid profile, attention scores and the tolerability in a group of ADHD children after receiving methylphenidate (MPH) and ω-3 PUFAs for 1 month.

METHODS

A combination of MPH (1 mg/kg/day) and eicosapentaenoic (EPA, 70 mg/day) + docosahexaenoic acids (DHA, 250 mg/day) was administered to 40 ADHD children (7-15 years). An analysis of serum fatty acids by gas chromatography and an assessment of attention by using the Magallanes Scale of Visual Attention (MSVA) were carried out before and after 1 month of treatment.

RESULTS

Our data revealed significant decreases of several ω-6 PUFAs, like arachidonic acid (P<0.0259). EPA and DHA concentrations increased by 27% and 3% respectively, and the ω-6/ω-3 index slightly decreased. The quality of attention significantly increased (P<0.026) and an improvement of ADHD core symptoms was reported both by parents and by teachers. No severe side effects occurred.

CONCLUSIONS

Results demonstrate that the combination of MPH and EPA+DHA at the tested doses has positive clinical effects and an adequate safety profile. Therefore, our study suggests that ω-3 PUFAs may represent a feasible and a safe adjuvant therapy in children with ADHD and might enhance the effects of MPH. Further long-term follow-up studies are required to confirm these initial findings.

Authors+Show Affiliations

Department of Pediatrics, School of Medicine, San Cecilio University Hospital, University of Granada, Granada, Spain - acheca1987@gmail.com. Aston Brain Centre, Aston University, Birmingham, UK - acheca1987@gmail.com.Department of Physiology and Biochemistry of Animal Nutrition (EEZ-CSIC), Estación Experimental del Zaidín (CSIC), Granada, Spain.Department of Physiology and Biochemistry of Animal Nutrition (EEZ-CSIC), Estación Experimental del Zaidín (CSIC), Granada, Spain.Department of Pediatrics, School of Medicine, San Cecilio University Hospital, University of Granada, Granada, Spain.Department of Pediatrics, School of Medicine, San Cecilio University Hospital, University of Granada, Granada, Spain.Department of Pediatrics, School of Medicine, San Cecilio University Hospital, University of Granada, Granada, Spain.

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

30419741

Citation

Checa-Ros, Ana, et al. "Early Monitoring of Fatty Acid Profile in Children With Attention Deficit And/or Hyperactivity Disorder Under Treatment With Omega-3 Polyunsaturated Fatty Acids." Minerva Pediatrica, vol. 71, no. 4, 2019, pp. 313-325.
Checa-Ros A, Haro-García A, Seiquer I, et al. Early monitoring of fatty acid profile in children with attention deficit and/or hyperactivity disorder under treatment with omega-3 polyunsaturated fatty acids. Minerva Pediatr. 2019;71(4):313-325.
Checa-Ros, A., Haro-García, A., Seiquer, I., Molina-Carballo, A., Uberos-Fernández, J., & Muñoz-Hoyos, A. (2019). Early monitoring of fatty acid profile in children with attention deficit and/or hyperactivity disorder under treatment with omega-3 polyunsaturated fatty acids. Minerva Pediatrica, 71(4), 313-325. https://doi.org/10.23736/S0026-4946.18.04975-7
Checa-Ros A, et al. Early Monitoring of Fatty Acid Profile in Children With Attention Deficit And/or Hyperactivity Disorder Under Treatment With Omega-3 Polyunsaturated Fatty Acids. Minerva Pediatr. 2019;71(4):313-325. PubMed PMID: 30419741.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Early monitoring of fatty acid profile in children with attention deficit and/or hyperactivity disorder under treatment with omega-3 polyunsaturated fatty acids. AU - Checa-Ros,Ana, AU - Haro-García,Ana, AU - Seiquer,Isabel, AU - Molina-Carballo,Antonio, AU - Uberos-Fernández,José, AU - Muñoz-Hoyos,Antonio, Y1 - 2018/11/07/ PY - 2018/11/14/pubmed PY - 2020/1/1/medline PY - 2018/11/14/entrez SP - 313 EP - 325 JF - Minerva pediatrica JO - Minerva Pediatr VL - 71 IS - 4 N2 - BACKGROUND: Cognitive effects of omega-3 polyunsaturated fatty acids (ω-3 PUFAs) might make them helpful in attention deficit/hyperactivity disorder (ADHD). However, the results derived from supplementation studies in children depend on the respective combinations and the study period. We aimed to investigate the serum fatty acid profile, attention scores and the tolerability in a group of ADHD children after receiving methylphenidate (MPH) and ω-3 PUFAs for 1 month. METHODS: A combination of MPH (1 mg/kg/day) and eicosapentaenoic (EPA, 70 mg/day) + docosahexaenoic acids (DHA, 250 mg/day) was administered to 40 ADHD children (7-15 years). An analysis of serum fatty acids by gas chromatography and an assessment of attention by using the Magallanes Scale of Visual Attention (MSVA) were carried out before and after 1 month of treatment. RESULTS: Our data revealed significant decreases of several ω-6 PUFAs, like arachidonic acid (P<0.0259). EPA and DHA concentrations increased by 27% and 3% respectively, and the ω-6/ω-3 index slightly decreased. The quality of attention significantly increased (P<0.026) and an improvement of ADHD core symptoms was reported both by parents and by teachers. No severe side effects occurred. CONCLUSIONS: Results demonstrate that the combination of MPH and EPA+DHA at the tested doses has positive clinical effects and an adequate safety profile. Therefore, our study suggests that ω-3 PUFAs may represent a feasible and a safe adjuvant therapy in children with ADHD and might enhance the effects of MPH. Further long-term follow-up studies are required to confirm these initial findings. SN - 1827-1715 UR - https://www.unboundmedicine.com/medline/citation/30419741/Early_monitoring_of_fatty_acid_profile_in_children_with_attention_deficit_and/or_hyperactivity_disorder_under_treatment_with_omega_3_polyunsaturated_fatty_acids_ DB - PRIME DP - Unbound Medicine ER -